Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Efficacy of 308-nm excimer laser for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Study Overview

• Status: Completed
• Conditions: Lichen Amyloidosis
• Intervention / Treatment: Radiation: 308-nm excimer laser

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Thailand
  • Bangkok
    • Bangkok, Bangkok, Thailand, 10330
      • King Chulalongkorn Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Patients, aged >18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathologic features

Exclusion Criteria:

• Those with cutaneous amyloidosis associated systemic diseases
• Pregnancy or lactating woman
• Those who are allergic to urea, olive oil
• Those who are photosensitive to ultraviolet radiation
• Those who had been previously treated with medications/ radiation/ laser within 3 months for systemic and 1 month for topical therapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control
Experimental: excimer laser	Radiation: 308-nm excimer laser; monochromator UVB laser (308nm)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Roughness evaluation by using Visioscan® VC98	The improvement of roughness evaluation	Change from baseline roughness at every 2 weeks up to 16 weeks

Collaborators and Investigators

• Sponsor: Chulalongkorn University
• Collaborators: Ratchadapiseksompotch Fund
• Investigators: Principal Investigator: Einapak Amnarttrakul, M.D., Chulalongkorn University

Study record dates

Study Major Dates

• Study Start (Actual): January 31, 2022
• Primary Completion (Actual): January 30, 2023
• Study Completion (Actual): March 2, 2023

Study Registration Dates

• First Submitted: February 20, 2017
• First Submitted That Met QC Criteria: February 26, 2017
• First Posted (Actual): March 1, 2017

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 9, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: lichen amyloidosis; Asians; 308-nm excimer laser; primary localized cutaneous amyloidosis
• Additional Relevant MeSH Terms: Metabolic Diseases; Skin Diseases; Genetic Diseases, Inborn; Proteostasis Deficiencies; Metabolism, Inborn Errors; Amyloidosis, Primary Cutaneous; Equipment and Supplies; Lasers; Optical Devices; Radiation Equipment and Supplies; Lasers, Excimer
• Other Study ID Numbers: CU_308excimer_amyloidosis

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes